1. Clinical Spectrum and Treatment Outcomes of Patients with ...
Sep 21, 2022 · The most effective treatments were steroid therapy and a ketogenic diet, which were also effective in reducing seizures and improving cognition.
1. Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63:1398-442.
2. Antiseizure Medication-Induced Alopecia: A Literature Review - PMC
Jun 9, 2023 · Levetiracetam (LEV). LEV is considered a broad-spectrum ASM. This drug was approved by the FDA in 1999 for the management of epilepsy [62].
Background: Adverse effects of antiseizure medications (ASMs) remain one of the major causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly reported side effects of ASMs. In this context, alopecia is one of the CSEs that ...
3. Short- and long-term efficacy of levamisole in children with steroid ...
In this study, we aimed to evaluate short- and long-term effects of levamisole therapy in steroid-sensitive nephrotic syndrome (SSNS) in children.
In this study, we aimed to evaluate short- and long-term effects of levamisole therapy in steroid-sensitive nephrotic syndrome (SSNS) in children. The study consisted of 29 SSNS patients who had been treated with levamisole for 12 months. Laboratory values and clinical data were analyzed for three separate periods for each patient: 1 year prior to the initiation of levamisole therapy (Pre-Lev), during 1 year of levamisole therapy (During-Lev), and the year following cessation of levamisole therapy (End-Lev). The level of proteinuria fell from median 135.0 (24.0–633.0) mg/h/m2 Pre-Lev to median 4.4 (2.4–654.0) mg/h/m2 During-Lev and median 4.8 (2.2–105.0) mg/h/m2 End-Lev (p = 0.0001, for each). Median relapse frequency fell from 4.0 (3.0–8.0) relapses/patient per year Pre-Lev to 0.0 (0.0–2.0) During-Lev (p = 0.0001) with 23/29 patients having no relapse and 0.0 (0.0–1.0) End-Lev (p = 0.0001) with 18/29 patients without relapse. During-Lev, all children had marked diminution in annual steroid burden from a median of 5582.0 (2137.0–17340.0) mg/m2 per year Pre-Lev to 2166.0 (840.0–9325.0) mg/m2 per year (p = 0.0001). End-Lev, the annual steroid burden also continued to fall, to 0.0 (0.0–5386.0) mg/m2 per year (p = 0.0001). The age and duration of NS were significantly higher in the children with relapses than in the children with sustained remission (p = 0.009 and p = 0.014, respectively). The side effects that are expected during levamisole therapy did not occur in our patients....
4. [PDF] Cushing syndrome induced by long-term use of corticosteroids in ...
In our case, diflucortolone valerate was administered at high doses for 4 months. As a result, suppressed serum cortisol lev- els clinically led to Cushing ...
5. Short- and long-term efficacy of levamisole in children with steroid ...
Laboratory values and clinical data were analyzed for three separate periods for each patient: 1 year prior to the initiation of levamisole therapy (Pre-Lev), ...
Purpose
In this study, we aimed to evaluate short- and long-term effects of levamisole therapy in steroid-sensitive nephrotic syndrome (SSNS) in children.
MethodsThe study consisted of 29 SSNS patients who had been treated with levamisole for 12 months. Laboratory values and clinical data were analyzed for three separate periods for each patient: 1 year prior to the initiation of levamisole therapy (Pre-Lev), during 1 year of levamisole therapy (During-Lev), and the year following cessation of levamisole therapy (End-Lev).
ResultsThe level of proteinuria fell from median 135.0 (24.0–633.0) mg/h/m2 Pre-Lev to median 4.4 (2.4–654.0) mg/h/m2 During-Lev and median 4.8 (2.2–105.0) mg/h/m2 End-Lev (p = 0.0001, for each). Median relapse frequency fell from 4.0 (3.0–8.0) relapses/patient per year Pre-Lev to 0.0 (0.0–2.0) During-Lev (p = 0.0001) with 23/29 patients having no relapse and 0.0 (0.0–1.0) End-Lev (p = 0.0001) with 18/29 patients without relapse. During-Lev, all children had marked diminution in annual steroid burden from a median of 5582.0 (2137.0–17340.0) mg/m2 per year Pre-Lev to 2166.0 (840.0–9325.0) mg/m2 per year (p = 0.0001). End-Lev, the annual steroid burden also continued to fall, to 0.0 (0.0–5386.0) mg/m2 per year (p = 0.0001). The age and duration of NS were significantly higher in the children with relapses than in the children with sustai...
6. (PDF) Short- and long-term efficacy of levamisole in children with ...
by Yilmaz Tabel. 2013, International Urology and Nephrology. See Full PDF Download PDF ... End-Lev, the annual steroid burden also continued ... The definitions for ...
Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome
7. Timing of vasoactive agents and corticosteroid initiation in septic shock
May 30, 2022 · Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. ... Subramanian S, Yilmaz M, Rehman A, Hubmayr RD, Afessa B, Gajic O. Liberal vs ...
Septic shock remains a health care concern associated with significant morbidity and mortality. The Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock recommend early fluid resuscitation and antimicrobials. Beyond initial management, the guidelines do not provide clear recommendations on appropriate time to initiate vasoactive therapies and corticosteroids in patients who develop shock. This review summarizes the literature regarding time of initiation of these interventions. Clinical data regarding time of initiation of these therapies in relation to shock onset, sequence of treatments with regard to each other, and clinical markers evaluated to guide initiation are summarized. Early-high vasopressor initiation within first 6 h of shock onset is associated with lower mortality. Following norepinephrine initiation, the exact dose and timing of escalation to adjunctive vasopressor agents are not well elucidated in the literature. However, recent data indicate that timing may be an important factor in initiating vasopressors and adjunctive therapies, such as corticosteroids. Norepinephrine-equivalent dose and lactate concentration can aid in determining when to initiate vasopressin and angiotensin II in patients with septic shock. Future guidelines with clear recommendations on the time of initiation of septic shock therapies are warranted.
8. [PDF] Clinical effect of prednisone combined with tripterygium wilfordii ...
Comparison of serum inflammatory factor lev- els between the two groups. A ... novic R, Yilmaz A, Ranchin B, Baskin E, Erdo- gan O, Remuzzi G, Firszt ...
9. [PDF] Clinical Spectrum and Treatment Outcomes of Patients with ...
Aug 15, 2022 · Steroid therapy and a ketogenic diet can be considered effective therapeutic options for patients with D/. EE SWAS. Keywords: Epilepsy; ...
10. [PDF] Coexistence of steroid-resistant minimal change disease and ...
Akpolat T, Akpolat I, Karagoz F, Yilmaz E, Kandemir B, Ozen S. Familial Mediterranean fever and glomerulonephritis and review of the literature. Rheumatol ...
11. Gautam Borthakur, MD - MD Anderson Cancer Center
Oct 24, 2024 · ... Yilmaz M. Unrecognized fluid overload during induction therapy ... Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev ...
Gautam Borthakur, M.D., Department of Leukemia, Division of Cancer Medicine
12. [PDF] KDIGO 2012 Clinical Practice Guideline for the Evaluation and ...
... lev e l race or ethnicity coeffic ient. CKD-EPI equation w ith. 4-lev e l race ... steroids did not contribute.115. Figure 14 | Association of CKD ...
13. Inflammatory Status Influences Aromatase and Steroid Receptor ...
Nov 29, 2007 · Aromatase mRNA lev- els were increased significantly in red ... Yilmaz B, Martin R, Ut- sunomiya H, Thung S, Gurates B, Tamura M ...
14. [PDF] Steroid Response Pattern Among Children with Nephrotic Syndrome ...
Oct 19, 2020 · High cholesterol lev- els have been shown to be associated with markedly lower albumin levels and patients with relapses in nephrotic syn- drome ...
15. Myoclonus-Ataxia Syndrome Associated with COVID-19
Apr 6, 2021 · Case 3: LEV, CLN, IVMP 250 mg/day for 3 days. Patient had delayed ... steroids. Encephalitis has been very well described in COVID-19 ...
Myoclonus-Ataxia Syndrome Associated with COVID-19
16. COENZYME Q10 - Uses, Side Effects, and More - WebMD
Heart damage caused by certain cancer drugs (anthracycline cardiotoxicity). Early research shows that taking coenzyme Q10 by mouth might protect the heart in ...
Learn more about COENZYME Q10 uses, effectiveness, possible side effects, interactions, dosage, user ratings and products that contain COENZYME Q10.